130 related articles for article (PubMed ID: 37417165)
21. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.
Zidane N; Dussart P; Bremand L; Bedouelle H
BMC Infect Dis; 2013 Jul; 13():302. PubMed ID: 23815496
[TBL] [Abstract][Full Text] [Related]
22. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
Ali S; Afzal S; Yousaf MZ; Shahid M; Amin I; Idrees M; Aftab A
Crit Rev Eukaryot Gene Expr; 2020; 30(3):199-206. PubMed ID: 32749106
[TBL] [Abstract][Full Text] [Related]
24. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
[TBL] [Abstract][Full Text] [Related]
25. Computational analysis of perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus.
Chakraborty S
F1000Res; 2016; 5():1150. PubMed ID: 27540468
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
27. A synthetic peptide analog of in silico-predicted immunogenic epitope unique to dengue virus serotype 2 NS1 antigen specifically binds immunoglobulin G antibodies raised in rabbits.
Guevarra LA; Boado KJO; Ceñidoza FBB; Imbao MRLM; Sia MJG; Dalmacio LMM
Microbiol Immunol; 2020 Feb; 64(2):153-161. PubMed ID: 31710119
[TBL] [Abstract][Full Text] [Related]
28. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
Aarthy M; Singh SK
Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
[TBL] [Abstract][Full Text] [Related]
30. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
31. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
[TBL] [Abstract][Full Text] [Related]
32. In Silico Comparative Analysis of Predicted B Cell Epitopes against Dengue Virus (Serotypes 1-4) Isolated from the Philippines.
Abesamis LMI; Aliping EGA; Armada FKGH; Danao MF; Del Valle PDB; Regencia ZJG; Baja ES; Ligsay AD
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016147
[TBL] [Abstract][Full Text] [Related]
33. Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes.
Kaushal N; Jain S; Baranwal M
J Mol Recognit; 2022 Sep; 35(9):e2961. PubMed ID: 35514257
[TBL] [Abstract][Full Text] [Related]
34. Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.
Rathore AS; Sarker A; Gupta RD
Appl Microbiol Biotechnol; 2020 May; 104(10):4333-4344. PubMed ID: 32232529
[TBL] [Abstract][Full Text] [Related]
35. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.
Crill WD; Hughes HR; Delorey MJ; Chang GJ
PLoS One; 2009; 4(4):e4991. PubMed ID: 19337372
[TBL] [Abstract][Full Text] [Related]
36. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
[TBL] [Abstract][Full Text] [Related]
37. Molecular Characterization and Identification of Potential Inhibitors for 'E' Protein of Dengue Virus.
Racherla RG; Katari SK; Mohan A; Amineni U; Badur M; Chaudhury A; Nagaraja M; Kodavala S; Kante M; Kalawat U
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632682
[TBL] [Abstract][Full Text] [Related]
38. Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).
da Silva AN; Nascimento EJ; Cordeiro MT; Gil LH; Abath FG; Montenegro SM; Marques ET
PLoS One; 2009 Oct; 4(10):e7425. PubMed ID: 19826631
[TBL] [Abstract][Full Text] [Related]
39. Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines.
Batista ICA; Quinan BR; Rocha Alves ÉA; Jangola STG; Oliveira ES; Colombarolli SG; Ferreira JGG; Rocha ESO; Kroon EG; de Assis RR; de Oliveira JG; Fiuza JA; Calzavara-Silva CE
Vaccine; 2020 Feb; 38(8):2005-2015. PubMed ID: 31982262
[TBL] [Abstract][Full Text] [Related]
40. In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever.
Subramaniyan V; Venkatachalam R; Srinivasan P; Palani M
J Biomed Res; 2017 Nov; 32(3):222-36. PubMed ID: 29497025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
